NexThera

NexThera is a biopharmaceutical R&D company dedicated to developing advanced therapeutic solutions and platforms, leveraging the unique strengths of its co-founders with their combined 20 years of experience and achievements in biomedical research. In addition to NT-101, ongoing projects include advancing a bio-better development platform and cancer cell-selective protein synthesis inhibition technology. The bio-better development platform utilizes the properties of self-assembling proteins and serves as a versatile system applicable to the development of various protein drugs and bio-improvement agents, including peptides, enzymes, and antibody fragments. This platform is currently being optimized following the completion of patent applications and candidate selection. Furthermore, the technology for selectively inhibiting protein synthesis in cancer cells was selected by the 2023 Korea Drug Development Fund for its innovation and practicality, receiving government research subsidies. Current R&D efforts are focused on successfully identifying lead compounds.